Market Noise Masks KERX’s Real Potential
Long Ideas - The spin doctors have done a great job pressuring Keryx BioPharmaceuticals (KERX) recently, pulling out all the stops to drive the stock down. Massive share … Continue Reading
Read NowMost Popular
Research Report Misses the Mark; A Second Chance to Own Keryx
Long Ideas - On Friday, February 1st, a report out from research firm IPD Analytics took nearly 22% out of Keryx Biopharmaceuticals (KERX) by questioning the novelty and … Continue Reading
Read NowPropThink’s Weekly Roundup
Most Popular - The event of the week? Phase III data for Zerenex, Keryx Biopharmaceutical’s phosphate binder, were released on Monday, with compelling results. PropThink has been covering … Continue Reading
Read NowQuality Investors Knock on Navidea’s Door; Validates Lymphoseek Potential
Long Ideas - On Wednesday, Navidea Biopharmaceuticals (NAVB) announced that two institutional investors, including J.P. Morgan Asset Management, purchased $4.8M shares of its common stock in an overnight … Continue Reading
Read NowENDP a Buyout Target; Valeant The Lead Suspect And Moves Quickly
Long Ideas - Reuters reported on Wednesday afternoon that, according to industry sources, Endo Health Solutions (ENDP) is in talks with potential buyers of the business. Our “Trouble … Continue Reading
Read NowIsis Pharmaceuticals: A Compelling Long-Term Story
Long Ideas - With the approval of Kynamro, we believe that Isis Pharmaceuticals (NASDAQ:ISIS) is a compelling long-term investment due to it’s additional pipeline candidates, multiple drug development … Continue Reading
Read NowAmpio Pharmaceuticals: Overbought and Under-Capitalized
Most Popular - Shares of Ampio Pharmaceuticals (AMPE) were on a tear in the past four weeks, climbing from $3.39 at the end of December to a recent … Continue Reading
Read Now